History

_x000D_ Dr Reddy's Laboratories was incorporated in 1984 in Hyderabad. It was established by Dr Anji Reddy with an initial capital outlay of ₹25 lakh. Mr. Reddy was one of the pioneers of the active pharmaceutical ingredients or APIs industry in India. Before establishing Dr. Reddy’s Laboratories, he had already co-founded two bulk drug manufacturing ventures._x000D_ _x000D_ The company made its beginning with the manufacture of Active Pharmaceutical Ingredients and Intermediates (APIs) and commenced operations with a single drug in a 60-tonne facility near Hyderabad. In the year 1986, the company shares were listed on the Bombay Stock Exchange. Thereafter, they entered the international market with exports of Methyldopa. In the year 1987, the company obtained the first USFDA approval for Ibuprofen API._x000D_ _x000D_ In 1991, the company began production of Omeprazole, which is one of its most popular drugs. In 1993, the Dr. Reddy’s Research Foundation was established, which focused on drug discovery, especially for cancer and diabetes. In 1998, they started their biologics business to offer affordable medicine to the Indian consumer. In 2003, the company launched its first generic product, i.e. Ibuprofen, under their label in the US. In 2019, the company entered the nutrition segment in India through the launch of Celevida._x000D_

Business Segments

_x000D_ Dr. Reddy's offers a portfolio of products and services, including Active Pharmaceutical Ingredients (APIs), custom pharmaceutical services, generics, biosimilars and differentiated formulations. The company focuses on areas including gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy's is today a global company with a strong presence abroad. Its major markets include - the USA, India, Russia, and Europe. _x000D_ _x000D_ The company has primarily 3 businesses:_x000D_

_x000D_
1. Pharmaceutical services and active ingredients production - This is the largest source of revenue for the company, bringing in roughly 83% of the revenue in FY 2022. As of September 2023, the company offers 400+ generic drugs at affordable costs by leveraging its integrated operations. Drugs related to the nervous system bring in the most revenue.
_x000D_
2. Global generic drug production - Dr. Reddy’s Laboratories works on API development to help its own generic drugs business become cheaper as well as to launch products in the market faster than its competitors.
_x000D_
3. Proprietary Products - This mostly involves the company developing various formulas to enhance efficiency and ease of use, among other factors.
_x000D_

_x000D_ As of March 2023, the company had 40 subsidiary companies abroad and 9 subsidiaries in India. Major ones include Dr. Reddy’s Laboratories Inc., Dr. Reddy’s Laboratories SA, and Betapharm Arzneimittel GmbH, among others. _x000D_

Key Personnel

_x000D_ Erez Israeli, CEO_x000D_ _x000D_ Erez Israeli is the Chief Executive Officer of Dr. Reddy’s Laboratories. He joined the company in April 2018 as Chief Operating Officer before becoming CEO in July 2019. Mr. Israeli has an MBA from Bar-Ilan University, Israel, as well as over 30 years of experience. He had earlier worked at Enzymotec, where he was the President and CEO. Before that, he worked at Teva Pharmaceuticals for 23 years. He has held a multitude of positions, especially in the field of sales and marketing._x000D_ _x000D_ G V Prasad, Co-chairman and MD_x000D_ _x000D_ Mr. Prasad joined the company in 1990. He oversaw Dr. Reddy’s growth from a mid-sized domestic operation to a major global pharma brand today, with a presence in 66 countries and a valuation of billions of dollars. His focus is on research, innovation, transparency, business ethics and leaner corporate structures. He also focuses on mentoring leaders driving innovation in science, technology and digitalisation._x000D_

Corporate Actions

_x000D_ Bonus Shares_x000D_ _x000D_ Dr Reddy’s Laboratories had announced a bonus share in 2006 in the ratio of 1:1._x000D_ _x000D_ Stock Splits_x000D_ _x000D_ Dr Reddy’s Laboratories had last split its shares from a face value of ₹10 to ₹5 in 2001._x000D_ _x000D_ Dr Reddys Laboratories has not announced any rights issues or buyback of shares so far._x000D_ _x000D_ Mergers and Acquisitions_x000D_

_x000D_
• In 2022-23, Dr. Reddy's Holdings Limited got merged with Dr Reddy's Laboratories Ltd. The merger became effective in April 2022.
_x000D_
• DRS LLC in Russia merged into Dr. Reddy's Laboratories LLC in July 2022. 
_x000D_
• In 2017, Dr. Reddy's Laboratories completed the acquisition of a 100% stake in Imperial Credit Private Limited, a Non-Banking Finance Company (NBFC), based out of Kolkata, for a consideration of ₹2.05 crore.
_x000D_
• In 2016, Dr. Reddy’s Laboratories acquired 6 OTC brands from Ducere Pharma to enter the consumer health field.
_x000D_
• In 2002, the company had made its first overseas acquisition in the form of BMS Laboratories Ltd. and Meridian Healthcare in the UK.
_x000D_

_x000D_

Financial Highlights

_x000D_

_x000D_
• The company’s sales revenue has gone up by more than 100% in the period between March 2013 and March 2023.
_x000D_
• On the other hand, the company’s net profits have increased by nearly 200% in the same period.
_x000D_
• The company’s net cash flows have been volatile over the past years. From being in negative for the last few years, it increased to ₹1,286 crore in FY 2021, dropped to ₹3 in FY 2022 and further declined to -₹907 in FY 2023.
_x000D_